Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Normanno N"'
Autor:
PACILIO C, MORABITO A, NUZZO F, GRAVINA A, LABONIA V, LANDI G, ROSSI E, MAIO E, DI MAIO M, D'AIUTO G, BOTTI G, NORMANNO N, CHIODINI, Paolo, GALLO, Ciro, PERRONE, F, DE MATTEIS A, NCI NAPLES BREAST CANCER GROUP
Publikováno v:
British Journal of Cancer
The aim of the study was to demonstrate the superiority of docetaxel and epirubicin vs docetaxel alone as first-line therapy in metastatic breast cancer patients pretreated with adjuvant or neoadjuvant epirubicin. We compared single agent docetaxel 1
Autor:
Nicola Normanno, Anna Maria Rachiglio, Giuseppe Antinolfi, Pietro Carotenuto, Renato Franco, Alfonso Illiano, Francovito Piantedosi, Alessandro Morabito, Gerardo Botti, Antonella De Luca, Cristin Roma, Raffaella Pasquale
Publikováno v:
Pharmacogenomics and personalized medicine
The epidermal growth factor receptor (EGFR) is expressed in the majority of non- small-cell lung cancer (NSCLC). However, only a restricted subgroup of NSCLC patients respond to treatment with the EGFR tyrosine kinase inhibitor (EGFR TKI) gefitinib.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aae62c090c8a3bfdfb573e7eb9bf1d1b
http://hdl.handle.net/11591/328837
http://hdl.handle.net/11591/328837
Autor:
Erika Martinelli, Teresa Troiani, Lucia Esposito, Nicola Normanno, Davide Ciardiello, Carmine Pinto, Evaristo Maiello, Chiara Cremolini, Tiziana Latiano, Vincenzo Famiglietti, Giuseppe Santabarbara, Giulia Martini, Antonio Avallone, Stefania Napolitano, Fortunato Ciardiello, Filippo Pietrantonio
Publikováno v:
Cancers
Volume 13
Issue 22
Cancers, Vol 13, Iss 5715, p 5715 (2021)
Volume 13
Issue 22
Cancers, Vol 13, Iss 5715, p 5715 (2021)
The single-arm phase II CAVE mCRC trial evaluated the combination of cetuximab plus avelumab as rechallenge strategy in RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients, with clinical response to first-line anti-EGFR-based chemotherapy
Autor:
Teresa Troiani, Federica Morano, M. Terminiello, Giuseppe Santabarbara, Evaristo Maiello, Davide Ciardiello, Carmine Pinto, Anna Nappi, Erika Martinelli, Vincenzo Famiglietti, Claudia Cardone, Alessandra Di Liello, C. Borrelli, Chiara Cremolini, Antonio Avallone, Filippo de Braud, Stefania Napolitano, N. Zanaletti, Daniela Renato, Lucia Esposito, Daniele Santini, Filippo Pietrantonio, Tiziana Latiano, Giulia Martini, Pietro Paolo Vitiello, Nicola Normanno, Francesca Marrone, Daniele Rossini, Fortunato Ciardiello, Alfredo Falcone
Publikováno v:
JAMA Oncol
IMPORTANCE: Rechallenge therapy with anti–epidermal growth factor receptor (EGFR) drugs has been suggested in patients with chemo-refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC) after initial response to anti–EGFR-based first-li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60be67165de23d28a233b66cf2cd6dac
http://hdl.handle.net/11568/1113694
http://hdl.handle.net/11568/1113694
Autor:
Giovanni Scambia, Cosimo Sacco, Giorgio Valabrega, Maria Carmela Piccirillo, Antonella Savarese, Pierosandro Tagliaferri, Rossella Lauria, Francesco Perrone, Ugo De Giorgi, Sabrina Chiara Cecere, Marilena Di Napoli, Saverio Cinieri, Gabriella Ferrandina, Ciro Gallo, Giulia Amadio, Maria Ornella Nicoletto, Vanda Salutari, Nicola Normanno, Sandro Pignata, Domenica Lorusso, Simona Losito, Giuseppa Maltese, Gennaro Daniele, Anna Maria Mosconi, Claudia Omarini, Alessandra Sacco, Carmela Pisano, Stefano Greggi, Simona Signoriello, Barbara Kopf, Francesco Raspagliesi
Publikováno v:
Gynecologic oncology. 153(3)
Background Cervical cancer cells often express Epidermal Growth Factor Receptor (EGFR). Cetuximab (CET), an anti-EGFR antibody, can be safely combined with carboplatin (C) and paclitaxel (P), a standard treatment for advanced/recurrent cervical cance
Autor:
Francesco Perrone, Simona Bevilacqua, Agnese Montanino, Simona Signoriello, Cesare Gridelli, Ciro Gallo, Massimo Di Maio, Antonio Rossi, Antonella De Luca, Gaetano Rocco, Raffaele Costanzo, Nicola Normanno, Alessandro Morabito
Publikováno v:
Lung Cancer. 85:314-319
Objectives Circulating tumor cells (CTCs) have been hypothesized to be a prognostic factor in small-cell lung cancer (SCLC), and different cutoffs have been proposed to identify patients at high risk. We assessed the prognostic value of CTCs in patie
Autor:
Giovanna Finocchiaro, Filippo de Marinis, Marcello Tiseo, Giulio Cerea, Alessandro Del Conte, Laura Giannetta, Maria Rita Migliorino, Rita Chiari, Marco Angelo Burgio, Francesca Mazzoni, Agnese Montanino, Alessandro Morabito, Federico Cappuzzo, Nicola Normanno, Roberta Buosi, Paolo Bidoli, Diego Cortinovis, Luisa Foltran, Silvia Ferrari
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 99
Objectives Although patients with advanced non-small cell lung cancer (NSCLC) and an activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR-tyrosine kinase inhibitors (TKI), most of them progress within 12 months fro
Autor:
G. Buonfanti, Ciro Gallo, A. De Matteis, Simona Signoriello, Vincenza Tinessa, Alessandro Morabito, F. Perrone, Mauro Piccirillo, Carmen Pacilio, Gennaro Daniele, E. De Maio, M. De Laurentiis, Roberta D’Aniello, G. Botti, Giuseppe Esposito, F. Di Rella, G. Landi, Elisa Rossi, Massimiliano D’Aiuto, M. Di Bonito, Nicola Normanno, G. De Feo, A. Bartiromo, G. Colantuoni, Secondo Lastoria, Piera Maiolino, M. Di Maio, V. Labonia, Pasqualina Giordano, Adriano Gravina, Francesco Nuzzo
BACKGROUND To measure bone mineral density (BMD) reduction produced by letrozole as compared with tamoxifen and the benefit of the addition of zoledronic acid. PATIENTS AND METHODS A phase 3 trial comparing tamoxifen, letrozole or letrozole+zoledroni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e36da332b666974bbc5593e0d069612
http://hdl.handle.net/11588/467894
http://hdl.handle.net/11588/467894
Publikováno v:
Breast Cancer Research and Treatment. 29:11-27
A number of different epidermal growth factor (EGF)-related peptides such as EGF, transforming growth factor alpha (TGF alpha), amphiregulin (AR), heregulin (HRG), and cripto-1 (CR-1), are coexpressed to varying degrees in both normal and malignant m
Autor:
Simona Losito, Amelia Casamassimi, Antonella De Luca, Nicola Normanno, David S. Salomon, Fortunato Ciardiello, Sudhir Agrawal, M P Selvam
A majority of human breast carcinomas co-express the epidermal growth factor (EGF)-like peptides CRIPTO (CR), amphiregulin (AR) and transforming growth factor alpha (TGF-alpha). MDA-MB-468 breast carcinoma cells express CR, AR and TGFalpha, while SK-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1646b64c56e1d307ec1245d1411f3ebb
http://hdl.handle.net/11591/231726
http://hdl.handle.net/11591/231726